NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Clinical trials for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy combo offers new hope for tough bladder cancer
Disease control Recruiting nowThis phase 3 trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemotherapy or immunotherapy. It is for people with a type of bladder cancer that has not responded to standard BCG therapy. The study aims to see if th…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New hope for bladder cancer patients: gene therapy targets tumors without surgery
Disease control Recruiting nowThis study tests a new drug, EG-70, given directly into the bladder for people with a type of early-stage bladder cancer called non-muscle invasive bladder cancer (NMIBC). It is for patients whose cancer did not respond to the standard BCG therapy, or who have not received enough…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE1, PHASE2 • Sponsor: enGene, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC